This is largely due to increased expression and activity of two key ectoenzymes, CD39 (ENTPD1) and CD73 (NT5E), on the surface of tumor cells, cancer-associated fibroblasts, endothelial cells, regulatory T cells (Tregs), and certain myeloid subsets [61,62,63,64,65]. This evidence concerns the gene NT5E and neoplasm.